APA (7th ed.) Citation

Bibi, D., Steiner, L., Krtalic, I., Juretic, M., Cetina-Cizmek, B., Komlosi, A., . . . Hallak, H. (2026). Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. Pharmaceutics, 18(5), 601. https://doi.org/10.3390/pharmaceutics18050601

Chicago Style (17th ed.) Citation

Bibi, David, Lilach Steiner, Iva Krtalic, Marina Juretic, Biserka Cetina-Cizmek, Andrea Komlosi, Pippa Loupe, Kristina Ferderber, and Hussein Hallak. "Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics." Pharmaceutics 18, no. 5 (2026): 601. https://doi.org/10.3390/pharmaceutics18050601.

MLA (9th ed.) Citation

Bibi, David, et al. "Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics." Pharmaceutics, vol. 18, no. 5, 2026, p. 601, https://doi.org/10.3390/pharmaceutics18050601.